|Company name||Alkermes Public Limited Company|
|Class period||February 17, 2017 – November 1, 2018|
|Lead plaintiff deadline||February 25, 2019|
|Court||Eastern District of New York|
According to the Complaint, the company made false and misleading statements to the market. Alkermes was advised by the FDA to use a specific protocol with its New Drug Application submission for ALKS 5461. The company subsequently failed to follow the protocol. After reviewing the submission, an FDA advisory committee decided in a 21 to 2 vote against approving ALKS 5461. Based on these facts, the company’s public statements were false and materially misleading throughout the class period.